Genetic Analysis

Allocation, subscription, and payment
The Subsequent Offering was subscribed to a total of approximately NOK 4.1 million in gross proceeds, equivalent to a subscription rate of approximately 58 percent. The issue costs amount to approximately NOK 1.0 million.

The Company's annual general meeting held on May 19, 2025, granted the board of directors with an authorization to increase GA's share capital in connection with the Subsequent Offering. Decision regarding allocation of shares and increase of the Company's share capital in connection with the Subsequent Offering was made by the Company's board of directors today, on June 18, 20235, pursuant to the authorization, in accordance with the principles of allocation described in the simplified disclosure document published by the Company on June 2, 2025.

Subscribers that are allocated shares in the Subsequent Offering who do not hold shares through a financial intermediary, can obtain information on the number of shares allocated to them and the corresponding amount to be paid by accessing investor services through their account manager with Euronext Securities Oslo (VPS) from today, June 18, 2025. Subscribers who do not have access to investors services may contact DNB to obtain information on the number of shares allocated to them. Subscribers who hold shares through a financial intermediary must contact their local broker, custodian or nominee bank, as applicable, to receive information about allocated shares in the Subsequent Offering.

The payment date for shares allocated to subscribers in the Subsequent Offering is June 23, 2025.

Shares subscribed in the Subsequent Offering may not be traded until the registration of the share capital increase with the Norwegian Register of Business Enterprises (No. Foretaksregisteret) and the shares have been delivered. Accordingly, allotment, registration and trading will not be made in any securities through Euronext Securities Oslo corresponding to Swedish paid and subscribed shares (BTA).

Completion of the Subsequent Offering is subject to payment of the aggregate subscription amount by all subscribers in the Subsequent Offering and registration of the share capital increase relating to the Subsequent Offering with the Norwegian Register of Business Enterprises. Subject to duly and timely payment of the subscription amount, it is expected that the share capital increase will be registered on or about June 26, 2025, and that the new shares will be delivered to subscribers shortly thereafter.
 

Number of shares and share capital
Following registration of the share capital increase pertaining to the Subsequent Offering with the Norwegian Register of Business Enterprises, the number of shares in GA will have increased by 4,813,194, from 64,273,847 shares to 69,087,041 shares, and the Company’s total share capital will amount to NOK 41,452,224.60 divided into 69,087,041 shares each with a nominal value of NOK 0.60.

Shareholders who did not participate in the Subsequent Offering will experience a dilution of approximately 7.0 percent to the share capital and the votes in the Company.

Allocation of shares to primary insiders
The Interim CFO, Tore Grøttum subscribed for and was allocated 200.000 shares in the Subsequent offering. Following the issuance and registration of the shares Tore Grøttum will own 1,834,840 shares in Genetic Analysis AS.

Advisors
In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.